Literature DB >> 20373865

Are tumoral factors responsible for host tissue wasting in cancer cachexia?

Michael J Tisdale1.   

Abstract

Both cytokines and tumor factors have been implicated in tissue loss in cancer cachexia. Loss of adipose tissue is most likely due to the tumor (and host) factor zinc-alpha2-glycoprotein because of its direct lipolytic effect, ability to sensitize adipocytes to lipolytic stimuli and increased expression in cachexia. TNF-alpha and the tumor factor proteolysis-inducing factor are the major contenders for skeletal muscle atrophy; both increase protein degradation through the ubiquitin-proteasome pathway and depress protein synthesis through phosphorylation of eukaryotic initiation factor 2 alpha. However, while most studies report proteolysis-inducing factor levels to correlate with the appearance of cachexia, there is some disagreement regarding a correlation between serum levels of TNF-alpha and weight loss. Furthermore, only antagonists to proteolysis inducing factor prevent muscle loss in cancer patients, suggesting that tumor factors are the most important.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20373865     DOI: 10.2217/fon.10.20

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  18 in total

1.  Fatty acid metabolism-the first trigger for cachexia?

Authors:  David A Sassoon
Journal:  Nat Med       Date:  2016-06-07       Impact factor: 53.440

Review 2.  Translational regulator eIF2α in tumor.

Authors:  Qiaoli Zheng; Jingjia Ye; Jiang Cao
Journal:  Tumour Biol       Date:  2014-03-09

3.  Oral resveratrol therapy inhibits cancer-induced skeletal muscle and cardiac atrophy in vivo.

Authors:  Scott Shadfar; Marion E Couch; Kibwei A McKinney; Lisa J Weinstein; Xiaoying Yin; Jessica E Rodríguez; Denis C Guttridge; Monte Willis
Journal:  Nutr Cancer       Date:  2011-06-09       Impact factor: 2.900

4.  Effects of conditioned media from murine lung cancer cells and human tumor cells on cultured myotubes.

Authors:  Blas A Guigni; Jos van der Velden; C Matthew Kinsey; James A Carson; Michael J Toth
Journal:  Am J Physiol Endocrinol Metab       Date:  2019-11-05       Impact factor: 4.310

Review 5.  Cancer cachexia: understanding the molecular basis.

Authors:  Josep M Argilés; Sílvia Busquets; Britta Stemmler; Francisco J López-Soriano
Journal:  Nat Rev Cancer       Date:  2014-10-09       Impact factor: 60.716

6.  Decreased response to cAMP in the glucose and glycogen catabolism in perfused livers of Walker-256 tumor-bearing rats.

Authors:  Hely de Morais; Priscila Cassola; Carolina Campos Lima Moreira; Suéllen Kathiane Fernandes Vilas Bôas; Glaucia Regina Borba-Murad; Roberto Barbosa Bazotte; Helenir Medri de Souza
Journal:  Mol Cell Biochem       Date:  2012-05-26       Impact factor: 3.396

7.  Effects of celecoxib and ibuprofen on metabolic disorders induced by Walker-256 tumor in rats.

Authors:  Camila Oliveira de Souza; Mirian Ayumi Kurauti; Flaviane de Fatima Silva; Hely de Morais; Glaucia Regina Borba-Murad; Fábio Goulart de Andrade; Helenir Medri de Souza
Journal:  Mol Cell Biochem       Date:  2014-10-31       Impact factor: 3.396

8.  Inhibitory effect of tumor necrosis factor α on gluconeogenesis in perfused rat liver.

Authors:  Aline Franco da Rocha; Thaís Fernanda Liboni; Carolina Campos Lima Moreira; Daniele Romani Miksza; Camila Oliveira de Souza; Flaviane de Fatima Silva; Glaucia Regina Borba-Murad; Roberto Barbosa Bazotte; Helenir Medri de Souza
Journal:  Mol Cell Biochem       Date:  2012-12-09       Impact factor: 3.396

9.  Changes in liver gluconeogenesis during the development of Walker-256 tumour in rats.

Authors:  Carolina Campos Lima Moreira; Priscila Cassolla; Ana Paula Segantini Dornellas; Hely de Morais; Camila Oliveira de Souza; Glaucia Regina Borba-Murad; Roberto Barbosa Bazotte; Helenir Medri de Souza
Journal:  Int J Exp Pathol       Date:  2013-02       Impact factor: 1.925

10.  Radiomics predicts risk of cachexia in advanced NSCLC patients treated with immune checkpoint inhibitors.

Authors:  Wei Mu; Evangelia Katsoulakis; Christopher J Whelan; Kenneth L Gage; Matthew B Schabath; Robert J Gillies
Journal:  Br J Cancer       Date:  2021-04-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.